Integrated Drug Discovery Drives Intra-Biotech Acquisition
Biotech, defying all predictions, has never consolidated. There are roughly as many companies today as there were three years ago, according to the Ernst & Young survey-1287 in 1996 vs. 1231 in 1993). But among leading discovery-based companies, acquisitions are beginning to be seen as a valuable business tool, though for very different reasons than consolidationists had proposed.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.